Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19965705 | 0.74 | CNR2 (0.45) | GPR183PDE2ADRD3CNR2CNR1 | |
| SCHEMBL13566120 | 0.71 | CNR2 (0.40) | GPR183PDE2ADRD3CNR2CNR1 | |
| SCHEMBL2662891 | 0.67 | PDE2A (0.43) | GPR183PDE2A | |
| SCHEMBL18768656 | 0.65 | PDE2A (0.41) | GPR183PDE2A | |
| SCHEMBL14446464 | 0.62 | CNR2 (0.40) | PDE2ADRD3CNR2CNR1 | |
| SCHEMBL16238040 | 0.61 | PDE2A (0.42) | GPR183PDE2ACFTR | |
| SCHEMBL18768688 | 0.61 | PTGS1 (0.34) | DRD3CNR2CNR1 | |
| SCHEMBL1350221 | 0.61 | PDE2A (0.40) | GPR183PDE2A | |
| SCHEMBL18879812 | 0.61 | CNR2 (0.38) | GPR183PDE2ADRD3CNR2CNR1 | |
| SCHEMBL24702403 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | GPR183 3614/4885PDE2A 3449/4885DRD3 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.